| 0.7097 0.051 (7.79%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.3 | 1-year : | 1.64 |
| Resists | First : | 1.11 | Second : | 1.4 |
| Pivot price | 0.86  |
|||
| Supports | First : | 0.63 | Second : | 0.52 |
| MAs | MA(5) : | 0.71 |
MA(20) : | 0.94 |
| MA(100) : | 0.95 |
MA(250) : | 0.87 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.4 |
D(3) : | 4.8 |
| RSI | RSI(14): 26.4 |
|||
| 52-week | High : | 1.59 | Low : | 0.52 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ VXRT ] has closed above bottom band by 21.1%. Bollinger Bands are 64.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.71 - 0.71 | 0.71 - 0.72 |
| Low: | 0.65 - 0.66 | 0.66 - 0.66 |
| Close: | 0.7 - 0.71 | 0.71 - 0.72 |
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Fri, 15 Mar 2024
Vaxart, Inc. (NASDAQ:VXRT) Q4 2023 Earnings Call Transcript - Yahoo Finance
Thu, 14 Mar 2024
Vaxart Inc (VXRT) Reports Full Year 2023 Financial Results - Yahoo Finance
Thu, 07 Mar 2024
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14 - GlobeNewswire
Wed, 06 Mar 2024
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director - GlobeNewswire
Thu, 29 Feb 2024
Vaxart Inc Launches New Equity Plan to Attract Talent - TipRanks.com - TipRanks
Mon, 26 Feb 2024
VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 174 (M) |
| Held by Insiders | 1.5696e+008 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 13,710 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.472e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -520.8 % |
| Return on Assets (ttm) | -42.5 % |
| Return on Equity (ttm) | -98 % |
| Qtrly Rev. Growth | 14 % |
| Gross Profit (p.s.) | 1160.71 |
| Sales Per Share | 1.31786e+007 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -70 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 1.04 |
| Dividend | 0 |
| Forward Dividend | 1.719e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2023-12-19 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|